|Description||Indeglitazar is a peroxisome proliferator-activated receptor (PPAR) pan-agonist. Phase II clinical trials for Type 2 diabetes mellitus was discontinued.|
|Solubility||Soluble in DMSO|
|Application||Type 2 diabetes mellitus|
|Quality Standard||In-house standard|
|Shelf Life||2 month in rt, long time|
|Current Developer||Originator Plexxikon|
Rosiglitazone is a potent antihyperglycemic agent and a potent thiazolidinedione insulin sensitizer with IC50 of 12, 4 and 9 nM for rat, 3T3-L1 and human adipoc...
Saroglitazar is a novel peroxisome proliferator-activated receptor (PPAR) agonist with predominant PPARα and moderate PPARγ activity as a drug for the treatment...
Pioglitazone significantly attenuates left ventricular (LV) cavity dilatation and dysfunction by echocardiography as well as LV end-diastolic pressure in mice w...
INT 131 is a hypoglycemic agent, displays robust glucose-lowering activity in rodent models of diabetes while exhibiting a reduced side-effects profile compared...
BMS-687453 is a potent and selective peroxisome proliferator activated receptor PPARα agonist. with an IC50 of 10 nM for human PPARalpha and approximately 410-f...
GW-590735 is a potent and selective agonist of PPARα. Its EC50 value is 4 nM for the expression a GAL4-responsive reporter gene and at least 500-fold selectivit...
A potent PPARα modulator
Elafibranor is an agonist of the peroxisome proliferator-activated receptor-α and peroxisome proliferator-activated receptor-δ. It induces resolution of nonalco...
WY 14643 (Pirinixic Acid) is a potent peroxisome proliferator and activator of PPARα with EC50 of 1.5 μM.
FH535 is a Wnt/β-catenin signaling inhibitor and also a dual PPARγ and PPARδ antagonist.
GW501516 is a potent and highly selective PPARβ/δ agonist, with EC50 of 1 nM, with 1000-fold selectivity over hPPARα and hPPARγ. Phase 4.
Inolitazone is an orally bioavailable PAPR-gamma inhibitor with potential antineoplastic activity. Inolitazone binds to and activates peroxisome proliferation-a...
GSK0660 is a selective PPARδ antagonist. GSK0660 blocks the effect of TNFα on the expressions of cytokines involved in leukocyte recruitment, including CCL8, CC...
CS-7017 monohydrate is a peroxisome proliferator activated receptor gamma (PPAR) agonist. It is a potential therapy for thyroid cancer and liposarcoma. It is al...
Indeglitazar is a peroxisome proliferator-activated receptor (PPAR) pan-agonist. Phase II clinical trials for Type 2 diabetes mellitus was discontinued.
ST247 is a selective and inverse peroxisome proliferator-activated receptor (PPAR)β/δ agonist with IC 50 value of 19 nm, 10-fold more potent than GSK0660 with I...
BM152054, a thiazolidinedione, revealed to be potent PPARg-activators in transient transfection assays in vitro.
JW74 is a tankyrase-specific inhibitor. JW74 affects cell cycle progression and induces apoptosis and differentiation in osteosarcoma cell lines. At the molec...
Bezafibrate (marketed as Bezalip and various other brand names) is a fibrate drug used for the treatment of hyperlipidaemia. It helps to lower LDL cholesterol a...
In vitro, the IC50 for growth inhibition is approximately 0.8 nM while anaplastic thyroid carcinoma (ATC) tumor growth was inhibited three- to fourfold in nude ...